Action plan
Neuro-Coop Team
We contribute
Biosecurity
PARTICIPATES IN MAINTAINING A DYNAMIC, ENVIRONMENTALLY FRIENDLY SMALL RUMINANT FARMING SECTOR IN THE CROSS-BORDER AREA.
Scientific expertise
6 REFERENCE PARTNERS IN TWO COUNTRIES: SPAIN AND FRANCE
Connections
NEUROLOGY SERVICES AND PATIENT ASSOCIATIONS
Project actions
Project actions
The Neuro-Coop project carries out a series of actions in the field of neuroscientific research on a cross-border basis between France, Spain and Andorra.
The aim of the project is to develop a network of specialists in neurodegenerative diseases in the cross-border area, from research centres and benchmarks in this type of disease and innovation in diagnostic and typing technologies for this type of disease in our territory.
Action 3:
Cross-border network of neurodegenerative diseases research institutions
Create a network between research institutions on both sides of the border, involving clinicians and patient associations, to disseminate information on innovation (diagnosis and therapy) and promote projects with patients: longitudinal studies with biological samples.
Medical specialists and patient associations
Organisation of information seminars and meetings with specialists and patient associations.
MARCH 2024 / SEPT 2026
Network of specialised research centres
Protocols developed by partners for sampling and processing of neurodegenerative disease samples are made available.
MARCH 2024 / SEPT 2026
Action 4:
Establishing the determinants of the clinical diversity of prions (One Health approach) and other neurodegenerative diseases caused by misfolded proteins
Analyse the clinical diversity of neurodegenerative diseases associated with misfolded proteins to assess strain variability, cross-seeding and risk of transmission
Clinical diversity
Misfolded proteins as determinants of clinical diversity in neurodegenerative diseases in the cross-border space. Creation and characterisation of a panel of malfunctioning protein strains in the cross-border region.
MARCH 2024 / SEPT 2026
Phenomenon
Cross-seeding
As a source of clinical diversity in neurodegenerative diseases caused by misfolded proteins
- Generation of a panel of products derived from the experiments of cross-seeding in vitro with the different proteins and protocols developed.
- Study of the consequences of the diversity of prions and prion-like proteins and their relative risk of iatrogenic transmission.
- Development of reports on the assessment of resistance to decontamination and the
decontamination resistance and transmission
transmission capacity of misfolded proteins
MARCH 2024 / SEPT 2026
Action 5:
Early diagnostic approaches and progression markers for prion and prion-like diseases
Improving early detection and diagnosis of protein-mediated diseases, including prion and prion-like diseases through the development and validation of new methods to detect misfolded proteins and the search for biomarkers in biological fluids.
Protocols
Improvement and fine-tuning of amplification methods in vitro of malplega proteinsdas Improved protocols for in vitro amplification of misfolded proteins.
MARCH 2024 / SEPT 2026
Scoreboards
Development and validation of a specific marker for the diagnosis of synucleopathies by magnetic resonance imaging.
Compounds for the MR diagnosis of synucleopathies.
MARCH 2024 / SEPT 2026
Diagnostic efficacy
Identification of new biomarkers and seeding activity in body fluids (CSF, blood and urine).
List of biomarkers and technical reports on their diagnostic efficacy.
MARCH 2024 / SEPT 2026
POCTEFA Objectives 2021-2027
Objectives
Diagnosis
Development of a specific marker for the diagnosis of synucleopathies by magnetic resonance imaging.
Biomarkers
Identification of biomarkers in body fluids
Sampling
Development of common sampling protocols
Analysis
Analysis of the clinical diversity of prion diseases
Diversity
Analysis of the clinical diversity of prion diseases other neurodegenerative diseases
Cross-seeding
Study of the phenomenon of cross-seeding
Evaluation
Assessment of decontamination resistance and transmission risk
Methodology
Improving diagnostic methods in vitro
English (UK) 
Español 
Français